MPX Expands Maryland Footprint With Opening of Health for Life White Marsh Dispensary

TORONTO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE: MPX; OTC: MPXEF) announced that the Company will open a new Health for Life dispensary in Nottingham, Maryland which is located at 4741 Ridge Rd, Nottingham, Maryland, 21236. The dispensary is operated by MPX’s indirect wholly-owned subsidiary, S8 Management LLC, through a management agreement with LMS Wellness, Benefit LLC (“LMS”), which provides all management services typically required by a dispensary facility to successfully operate. This is the Company’s third dispensary in Maryland, following the opening of its flagship Health for Life dispensary in Bethesda, in August 2018 and Health for Life dispensary in Baltimore, in October 2018.

The dispensary, in line with others under the Health for Life brand, features copper accents, rustic wood paneling and navy blue walls, is prepared to welcome upward of 100 patients during its first week of business. Fully-trained consultants will be available to inform and assist Maryland patients holding a medical cannabis commission ID card with information regarding the flower, topicals, concentrates and other forms permitted under Maryland regulations, offered at the dispensary.

“Marylanders are increasingly familiar with The Health for Life brand and the impact it has on their community,” said Julie Winter, MPX’s Senior Vice President of East Coast Operations. “They are now able to find us in three locations and have come to rely on us as a reputable source for patient education and reliable information on cannabis, as well as quality, consistent medicine.”

The Health for Life White Marsh dispensary is located off of the highly-trafficked Ridge Road in the community of Nottingham and within two miles of the White Marsh Mall. Health for Life White Marsh is open to patients Sunday through Saturday. Operating hours can be found in the Health for Life website.

About MPX Bioceutical Corporation
MPX, through its wholly-owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis enterprises in Arizona operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical Area. With the acquisition of The Holistic Center, MPX added another operating medical cannabis enterprise to its footprint in Arizona.

GreenMart of Nevada NLV, LLC (“GreenMart NV”) is an award winning licensed cultivation, production and wholesale business, licensed for both the medical and “adult use” sectors in Las Vegas, Nevada, and is already selling wholesale into the Nevada medical cannabis market. GreenMart NV has also optioned suitable locations and intends to enter the higher-margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under the “Health for Life” brand.

In Massachusetts, MPX is building out and will operate a cultivation and production facility as well as up to three dispensaries and manages three full service dispensaries and one producer in Maryland.

In Canada, MPX has acquired Canveda, which has received its cultivation license from Health Canada, will operate a cultivation and production facility in Peterborough, Ontario. The Company also leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will continue its efforts to develop its legacy nutraceuticals business.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

On behalf of the Board of Directors

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO

For further information, please contact:

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
T: +1-416-840-3725
info@mpxbioceutical.com
www.mpxbioceutical.com

Media Contact:
Anne Donohoe 
KCSA Strategic Communications
212-896-1265 
adonohoe@kcsa.com 

Investor Contact:
Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
212-896-1233 / 212-896-1203 
pcarlson@kcsa.com / ebarker@kcsa.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/89fd66b1-2163-4401-aa99-242cc000d271

Source: MPX Bioceutical Corporation

Released October 29, 2018

Victor Madril